Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Post by Golddetectoron Jan 12, 2022 7:22pm
181 Views
Post# 34310753

Pharma not cannabis

Pharma not cannabis This hitting a 52 week low ahead of phase II fda results do not make a lot of sense to me. At mc 40M us while phase II drug is more than 10 times of that not considering ard003 or Reduvo.  Mc is more like early stage pharma at preclinical stage not even into phase I.
main reason imo is ppl considering this as cannabis stock for whatever reason. However, the recent pullback is mainly due overreacted to bad financing done in December. However, 13 million shares cannot have that much impact. Even most of shorts coved above 13 or 14cents. Short volume reduced by 65% last two weeks tells something. Even after covid sp was not at this level. We did not even have phase 2 on at that time. Massively oversold imo. I bought more at 11.5c and planning to add more. 
<< Previous
Bullboard Posts
Next >>